TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
59 hedge funds and large institutions have $31.4M invested in TCR2 Therapeutics Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 11 closing their positions.
50% more capital invested
Capital invested by funds: $21M → $31.4M (+$10.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 63 → 59 (-4)
29% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 17
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$890K |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$763K |
| 3 |
Morgan Stanley
New York
|
+$147K |
| 4 |
SC
Sagefield Capital
Dallas,
Texas
|
+$59.1K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$335K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$234K |
| 3 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$200K |
| 4 |
Two Sigma Advisers
New York
|
-$187K |
| 5 |
Millennium Management
New York
|
-$146K |
TCRR Hedge Fund Activity: Q1 2023 in Review
59 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q1 2023, worth a combined $31.4M — up 50% from $21M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TCRR and 7 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 12 added.
The largest buyer was Tang Capital Management, adding an estimated $890K. The largest seller was Renaissance Technologies, cutting an estimated $335K.
- 59 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q1 2023, down from 63 in Q4 2022.
- Funds reported $31.4M of TCR2 Therapeutics Inc. Common Stock stock for Q1 2023, up 50% quarter-over-quarter.
- 7 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q1 2023 and 11 closed out, a net change of -4 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q1 2023 was Tang Capital Management, an estimated $890K added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q1 2023 was Renaissance Technologies, an estimated $335K sold.
Based on aggregated 13F filings for Q1 2023.